Lead optimization cycles are too slow

Category: Drug Discovery

Design-make-test-analyze loops drag on, with each iteration costly in chemistry time and assay resources.

Moving from hit to clinical candidate means many design-make-test-analyze cycles, each costly in chemistry and assay time. Compressing those cycles is a direct lever on discovery speed and cost. Generative chemistry and physics-/ML-based design tools propose and rank candidate molecules to optimize potency, selectivity, and developability with fewer iterations.

How AI helps compress lead-optimization cycles

Lead optimization is a repeated design-make-test-analyze loop, and each turn costs chemistry and assay time. Generative and predictive design tools attack the design step: they propose new molecules and rank them against several objectives at once — potency, selectivity, and developability properties — so chemists spend synthesis effort on the most promising ideas rather than exploring a vast space by hand. Physics- and machine-learning-based models estimate how a proposed structure is likely to behave before anyone makes it. The aim is fewer, better-informed iterations, not automated chemistry. These tools generate and prioritize hypotheses; medicinal chemists judge synthetic feasibility, novelty, and strategy, and the assays remain the arbiter of whether a design actually works. Predictions guide where to spend bench time, not what to conclude.

What to evaluate before buying generative design AI

The central question is whether the models are predictive for your chemistry and your targets. A tool that ranks molecules well on public benchmarks may do poorly on your series, so ask how models are trained and calibrated, whether they can learn from your own assay data as a project progresses, and whether they report confidence so a chemist knows when a prediction is an extrapolation. Synthetic accessibility matters as much as predicted potency: a design no one can make is not a lead. Evaluate whether proposed molecules are realistically synthesizable, how the tool handles multi-parameter trade-offs rather than optimizing one property in isolation, and how it fits into your existing design and data-capture workflow.

How teams typically get started

A practical entry point is running one active optimization project alongside the normal medicinal-chemistry process: let the tool propose and rank candidates in parallel and compare its suggestions against what the team designs and what the assays return. That builds evidence on whether the models are predictive for your chemistry before they drive synthesis decisions, and helps chemists calibrate how much weight to give the rankings.

AI Use Cases That Address This Problem

  • ADMET & Toxicity Prediction
  • Hit Identification & Lead Optimization

Frequently asked questions

How does generative AI design new molecules?

Generative models learn patterns from chemical and activity data and propose novel structures predicted to meet defined objectives, while scoring models rank those proposals on properties like potency and selectivity. The result is a prioritized set of design ideas for chemists to evaluate — the software suggests, and the team decides what to make.

Can AI-designed molecules be trusted without synthesis and testing?

No. A predicted property is a hypothesis until an assay confirms it, and models can be confidently wrong on chemistry unlike their training data. The value is in choosing which molecules to synthesize and test, which narrows an enormous design space; the laboratory remains the source of truth.

Do these tools replace medicinal chemists?

No credible platform does. Chemists judge synthetic feasibility, novelty, intellectual-property position, and project strategy, and they own the design decisions. The tools handle scale — proposing and ranking far more options than a person could enumerate — so chemists can focus their judgment on the candidates that matter.

What should we ask a lead-optimization vendor?

Ask how their models were trained and validated, how they perform on chemistry similar to your series, whether they optimize multiple parameters together, how they account for synthetic accessibility, and whether the system learns from your assay results over time. A parallel pilot on a live project is the most honest test.

AI Vendors for This Problem

Evidence & Outcomes

Eli Lilly collaboration worth up to $670 million to discover novel therapies

Genesis Therapeutics (now Genesis Molecular AI) entered a strategic collaboration with Eli Lilly to discover novel therapies for up to five targets across a range of therapeutic areas using its Genesis Molecular AI drug-discovery platform, receiving $20 million upfront with a potential total value of up to $670 million.

Vendor: Genesis Molecular AI · press release (Genesis Therapeutics (Business Wire)) · 2022-05-03 — Partner: Eli Lilly and Company

Nimbus TYK2 program (TAK-279) acquired by Takeda for $4 billion upfront

A selective TYK2 inhibitor discovered using Schrödinger's physics-based computational platform (developed by Nimbus Therapeutics) was acquired by Takeda for $4 billion upfront, demonstrating commercial validation of a computationally designed clinical asset.

Vendor: Schrodinger · press release (Nimbus Therapeutics) · 2022-12-13 — Partner: Nimbus Therapeutics / Takeda

Eli Lilly AI and robotics drug-discovery collaboration

XtalPi and Eli Lilly announced a collaboration to apply XtalPi's AI and robotics-driven drug discovery platform to uncover first-in-class small-molecule therapeutics.

Vendor: XtalPi · news (Pharmaceutical Executive) · 2023-06-01 — Partner: Eli Lilly

Cube Biotech collaboration to design novel Amylin Receptor agonists

Iktos and Cube Biotech announced a strategic collaboration to discover novel small-molecule agonists of the Amylin Receptor, pairing Iktos's AI-driven generative design platform with Cube Biotech's membrane protein production and purification technologies.

Vendor: Iktos · press release (Iktos (PR Newswire)) · 2025-01-10 — Partner: Cube Biotech

Pfizer collaboration expanded for next-generation molecular modeling

XtalPi announced an expansion of its research collaboration with Pfizer to build a next-generation molecular modeling platform for drug discovery, applying XtalPi's AI and robotics capabilities to improve the accuracy of computational predictions.

Vendor: XtalPi · press release (XtalPi (PR Newswire)) · 2025-06-29 — Partner: Pfizer

Pierre Fabre Laboratories oncology drug-discovery collaboration

Pierre Fabre Laboratories and Iktos announced an integrated drug-discovery collaboration to identify and develop novel small-molecule candidates in oncology, with Iktos applying its AI-driven generative design platform alongside Pierre Fabre's medicinal chemistry, biology, and preclinical development.

Vendor: Iktos · press release (Iktos (PR Newswire)) · 2026-01-09 — Partner: Pierre Fabre Laboratories